Cordlife Group (CLIFF) 0.9865 $CLIFF
Golden Meditech Proposes to Purchase CCBC Convertible Notes Held by Magnum and CCBC Convertible Notes and CCBC Shares Held by CGL
PR Newswire - Fri May 08, 8:05AM CDT
Golden Meditech Holdings Limited ("Golden Meditech", or the "Company", together with its subsidiaries collectively as the "Group", 801.HK; 910801.TW), a leading integrated healthcare enterprise in China announced today that it has entered into an agreement (the "Magnum Agreement"

with Magnum Opus International Holdings Limited ("Magnum"

to purchase the 7% senior convertible notes due 2017 with an aggregate outstanding principal amount of US$25 million (equivalent to approximately HK$194 million) (the "Magnum Note"

issued by China Cord Blood Corporation ("CCBC"

, a non-wholly owned subsidiary of the Group. Golden Meditech also entered into an agreement (the "CGL Agreement"

with Cordlife Group Limited ("CGL"

to purchase the 7% senior convertible notes due 2017 with an aggregate outstanding principal amount of US$25 million (equivalent to approximately HK$194 million) (the "CGL Note"

issued by CCBC and 9.13% of the issued share capital of CCBC (the "CGL Sale Shares"

.
China Cord Blood Corporation Receives Notice of Transaction Regarding its 7% Senior Convertible Note Due 2017 Held by Golden Meditech
PR Newswire - Mon Aug 25, 6:00AM CDT
China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"

, China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company has been informed that Magnum Opus International Holdings Limited ("Magnum"

, a private vehicle that is controlled by CCBC Chairman Mr. Yuen KAM and involves the CCBC management team, together with Cordlife Group Limited ("Cordlife"

, a Singapore listed company and substantial shareholder of the Company, have agreed to purchase the Company's outstanding 7% senior convertible note due 2017 (the "Note"

held by Golden Meditech Holdings Limited ("Golden Meditech"

, CCBC's parent company, for a total consideration of approximately $88.1 million.
CO: 6.13 (+0.01)
China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy
PR Newswire - Wed Jul 23, 4:00AM CDT
China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"

, China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, and Cordlife Group Limited ("Cordlife"

, a multi-product healthcare company catering to the mother and child segment, today announced that the two companies have joined forces in assisting patients across the PRC, Singapore, Hong Kong, Indonesia, India, the Philippines and Malaysia to identify suitable cord blood matching units for stem cell therapy.
CO: 6.13 (+0.01)